...
首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: Implications for specific immunotherapy
【24h】

Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: Implications for specific immunotherapy

机译:草花粉过敏患儿IgE对Ph草的分子特征:对特异性免疫疗法的启示

获取原文
获取原文并翻译 | 示例

摘要

Background: The so-called component-resolved immunotherapy of allergies proposes an immunization tailored to the molecular sensitization profiles of individual patients. Objectives: We sought (1) to investigate the profiles of IgE sensitization to Phleum pratense in children with grass pollen allergy and (2) to define the compatibility of these profiles with a mixture of recombinant allergenic molecules of P pratense previously proposed for specific immunotherapy. Methods: We examined 200 children (age, 4-18 years; 126 boys) with allergic rhinitis, asthma, or both ascertained through validated questionnaires. Each child underwent skin prick testing (ALK-Abelló) and serum IgE assays (ImmunoCAP, Phadia) with 9 pollen extracts. Sera reacting against P pratense were tested for the individual molecules (rPhl p 1, rPhl p 2, rPhl p 4, nPhl p 4, rPhl p 5b, rPhl p 6, rPhl p 7, rPhl p 11, and Phl p 12). Through a combinatorial approach, the IgE individual sensitization profiles were matched against an experimental allergen-specific immunotherapy (SIT) preparation containing Phl p 1, Phl p 2, Phl p 5, and Phl p 6. Results: Among the 176 of 200 children with IgE sensitization to P pratense extract, 39 profiles of sensitization to the 8 allergenic molecules tested (cutoff, 0.35 kU/L) were identified. This high heterogeneity was reduced by considering only 6 or 4 P pratense molecules but not by increasing the cutoff levels of IgE positivity. The molecular profile of the experimental SIT preparation matched that of 7 (4%) of 176 patients only; the remaining 169 patients were classified in 4 mismatch categories: underpowered (29%), overpowered (32%), underpowered/overpowered (32%), and unrelated (3%). Conclusions: IgE sensitization profiles to P pratense are highly heterogeneous. Molecularly designed SIT preparations tailored to patients' needs should consider this high heterogeneity and be driven by locally performed population studies.
机译:背景:所谓的过敏性成分分解免疫疗法提出了一种针对个别患者的分子致敏特性进行量身定制的免疫方法。目的:我们寻求(1)研究草花粉过敏儿童对IgE致病性对Phleum pratense的敏感性,(2)定义这些特征与先前提议用于特异性免疫疗法的P pratense重组过敏原分子混合物的相容性。方法:我们检查了200名儿童(年龄为4-18岁;男126名),通过有效的问卷调查确定了过敏性鼻炎,哮喘或二者兼有。每个孩子都用9种花粉提取物进行皮肤点刺试验(ALK-Abelló)和血清IgE测定(ImmunoCAP,Phadia)。测试针对P.pratense反应的血清中的各个分子(rPhl p 1,rPhl p 2,rPhl p 4,nPhl p 4,rPhl p 5b,rPhl p 6,rPhl p 7,rPhl p 11和Phl p 12)。通过组合方法,将IgE个体致敏特性与包含Phl p 1,Phl p 2,Phl p 5和Phl p 6的实验性变应原特异性免疫疗法(SIT)制剂相匹配。结果:在200名儿童中,有176名患有对P.pratense提取物的IgE致敏,鉴定了对8种过敏原分子的敏感性(截止值为0.35 kU / L)的39种谱。仅通过考虑6个或4个P诱捕分子可以降低这种高异质性,而不能通过提高IgE阳性的临界水平来降低。实验性SIT制剂的分子谱仅与176例患者中的7例(4%)相符。其余169位患者被分为4个不匹配类别:动力不足(29%),动力过度(32%),动力不足/动力过度(32%)和不相关(3%)。结论:对P. Pratense的IgE致敏特性高度异质。根据患者需求量身定制的分子设计的SIT制剂应考虑到这种高度的异质性,并应由当地进行的人群研究来推动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号